Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
2001 1
2002 1
2003 1
2004 3
2005 1
2006 1
2007 3
2008 2
2009 4
2010 4
2011 1
2012 5
2013 3
2014 4
2015 9
2016 14
2017 8
2018 16
2019 10
2020 14
2021 10
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

108 results
Results by year
Filters applied: . Clear all
Page 1
Driving CAR T-cells forward.
Jackson HJ, Rafiq S, Brentjens RJ. Jackson HJ, et al. Among authors: brentjens rj. Nat Rev Clin Oncol. 2016 Jun;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. Epub 2016 Mar 22. Nat Rev Clin Oncol. 2016. PMID: 27000958 Free PMC article. Review.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Park JH, et al. Among authors: brentjens rj. N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919. N Engl J Med. 2018. PMID: 29385376 Free PMC article. Clinical Trial.
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ. Rafiq S, et al. Among authors: brentjens rj. Nat Biotechnol. 2018 Oct;36(9):847-856. doi: 10.1038/nbt.4195. Epub 2018 Aug 13. Nat Biotechnol. 2018. PMID: 30102295 Free PMC article.
Novel immunotherapies in lymphoid malignancies.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Batlevi CL, et al. Among authors: brentjens rj. Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Nat Rev Clin Oncol. 2016. PMID: 26525683 Free PMC article. Review.
Toxicity and management in CAR T-cell therapy.
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Bonifant CL, et al. Among authors: brentjens rj. Mol Ther Oncolytics. 2016 Apr 20;3:16011. doi: 10.1038/mto.2016.11. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27626062 Free PMC article. Review.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ. Smith EL, et al. Among authors: brentjens rj. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. doi: 10.1126/scitranslmed.aau7746. Sci Transl Med. 2019. PMID: 30918115 Free PMC article.
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Boyiadzis MM, et al. Among authors: brentjens rj. J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. J Immunother Cancer. 2018. PMID: 30514386 Free PMC article. Review.
108 results